Friday, June 2, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Funding News

Vaccine and Treatment Evaluation Units Awards

by Global Biodefense Staff
September 17, 2013

Map of National Vaccine Evaluation and Treatment Units (VETU)The National Institute of Allergy and Infectious Diseases (NIAID) has made multiple funding awards in support of Vaccine and Treatment Evaluation Units (VTEU).

The VTEUs, supported by the NIAID since the 1960’s, have designed and conducted a broad range of clinical studies and clinical trials of bacterial, viral and parasitic vaccines, therapeutics, and other biologics and drugs as preventive and therapeutic measures against infectious diseases in people of all ages and risk categories.

The award amounts for each institution are a minimum value of $100,000 and maximum of $951,702,000. The recipients are:

  • Baylor College of Medicine
  • Children’s Hospital Medical Center
  • Duke University
  • Emory University
  • Group Health Research Institute
  • University of Iowa
  • Saint Louis University
  • University of Maryland, Baltimore
  • Vanderbilt University Medical Center

The VTEU contractors must be able to perform identification, design, development, implementation, analysis and reporting of clinical studies and clinical trials. Tasks and support functions executed by the organizations improve the understanding, diagnosing, treating, and preventing infectious diseases caused by viral, bacterial, parasitic and fungal pathogens, including the National Institute of Allergy and Infectious Diseases (NIAID) Priority Biodefense Pathogens and emerging infectious disease pathogens.

The effort was a re-competition of existing contracts due to expire on or about October 31, 2014. Approximately 40 clinical trials and clinical studies have been conducted during the past three years under these contracts, several in a compressed time frame to address emergent public health research needs, for example the 2009 H1N1 influenza pandemic.

The awards were announced under Solicitation Number: RFP-NIAID-DMID-NIHAI2012144.

Tags: AwardsInfluenzaPandemicVaccines

Related Posts

Vials of finished vaccines
Funding News

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics
Industry News

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023
Medical Countermeasures

Scientists Design Molecule to Slow SARS-Cov-2 Infection

March 29, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Load More

Latest News

Vials of finished vaccines

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

April 26, 2023
Biodefense Headlines – 25 April 2023

Biodefense Headlines – 25 April 2023

April 25, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2023 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2023 Stemar Media Group LLC